Innovation driven by experience
Our Pre-clinical Biosciences group are your ideal partners in any study needs from a single source. Our extensive experience gives us a confidence in our data that provides an accurate and balanced assessment of pre-clinical safety, even on short timescales.
If you want to develop a novel compound into a safe and effective treatment, we can deliver a package of studies tailored for each compound in development, while also confidently and accurately assessing safety data.
And to ensure your product goes beyond pre-clinical regulatory requirements, getting a significant head start to proof of concept and beyond, you’ll benefit from the expertise of our consulting and project management teams.
Our early-stage efficacy evaluations to aid candidate selection overcome the challenges of taking a pharmaceutical new chemical entity from drug discovery through to IND submission and First in Man dosing.
We ensure a robust discovery process by early evaluation of a biological target (Early Safety Prediction) and raising early possible structure related effects of a molecule (Computational Toxicology).
Our unique ‘First in Man-enabling’ fully integrated drug development program provides the mandatory core battery of safety studies and also a series of recommended in vitro drug metabolism studies to enhance understanding of the pharmacokinetic profile and metabolism.
Emerging Drug Technologies
Our immunology expertise and immunoassay platform are specifically designed to give you the advantage in biologics projects. Add our strong molecular expertise, we can also perform the pre-clinical safety evaluation, bringing even greater efficiencies.
- Safety Pharmacology
- General Toxicology
- Genetic Toxicology
- Immunoassays & Biotherapeutics
- Drug Metabolism & Pharmacokinetics
- Pre-clinical Bioanalysis